OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Evening All!

Perked up a bit now after having a look on the Growth Company Investor website
which showed company announcements for OXB.

Man Financial Ltd, Credit Agricole S.A., UBS AG and two companies linked with
Boris Jordon (Sulidad Investment and Trade and Sputnik) were still
continuing to build up their stakes yesterday. They were purchasing stock at
between 25.87p -27p.

Do they know something we do not? Why are they continuing to add to their
holdings on a daily basis and pay whatever the market price is?

Next week will be very interesting will the price accelerate up or continue to
fall? Will I pull tonight or not? No don't answer that one please.

Enjoy your weekends. Next week the drama continues.

1704 - for relatively short-term holders looking for quick gains it would certainly help if OXB was being courted by a big pharma. I will look out for any news in the weekend papers - although probably it will simply be more conjecture and unfounded rumour.

Pachandl

Good to hear from you and as usual I fully agree with your observation.

When I first invested in the stock less than a month ago I saw it as a long
term hold. How was I to know a merger or take over bid would occur (still not
sure what type of talks are taking place or who the other company is)? Don't
get me wrong I'm not really complaining. After all I've banked a nice and
quick gain.

However, it is interesting to see that certain institutions are continuing to
invest whether the price rises or drops. Are they being shrewd or reckless?
Is it a big pharma negotiating with OXB or a company the same size? Some
people are in on the know but I'm not one of them (Grrrrrrrr).

Although I am intrigued by the actions of these investors I would not base my
own decisions on their buying. I remember last year when a large American
Investor (K Capital) was stake building in Jarvis PLC viewing it as a recovery
play needless to say they lost millions.

I will also be skimming through all the papers over the weekend and flicking
through the Bloomberg TV Business Channel. In fact I will be on annual leave
and so will be able to watch Bloomberg TV for longer periods than I can now.

The current merger/bid talks are real 'cloak and dagger' stuff and know information about the progress of the talks seems to be leaking out. Not sure it will be any different this weekend.

I cannot wait for Monday morning when the market opens.Let the fun begin.

Dragged off to the shops today but checked the standard websites/papers on my return -certainly no indication of anything on OXB, rumour or fact. Perhaps tomorrow? Still, at least one of my other holdings, SKP, got a mention in the FT today so can't complain.

Have seen nothing in the Sunday papers regarding OXB - they are very good at stopping any leaks it seems.

Citywire.co.uk
Published: 07:00 Sunday 30 January 2005 < PREV | 1 | 2 | NEXT > TOTAL PAGES: 2
By: Graeme Davies, Investment Correspondent Back To Latest News Printable Version

Related Articles
Shrewd Snapshot: Jordan builds in Oxford:
07:00 Wed 26 January 2005 read
Shrewd Snapshot: Oxford Biomedica bags more Russian interest:
07:00 Sun 23 January 2005 read

Russian entrepreneur Boris Jordan has added to his holding at Oxford Biomedica and Swedish activist Peter Gyllenhammar has added to his stake at European Colour.

* Jordan's Sputnik vehicle snapped up another 166,666 shares on Thursday at 26.75p each to take its total holding in the 101 million gene-based therapeutics business (OXB) to 4.15 million shares or 1.2%.

The American-born Russian banking entrepreneur's vehicle is acting in concert with Garboldi Investment and Sulidad Invest & Trade and the three vehicles own more than 3% of Oxford between them.

Oxford's shares shot up earlier this month when it announced it was in merger talks with an unnamed third party however after a rise from 16.75p to 27p this month it gave up 1.25p on Friday to close at 25.75p.

Jordan made his fortune advising on Russia's privatisations and also set up its first Western-style investment bank. Oxford's shares drifted in the second half of last year as progress stalled on its licensing deals.

What a brilliant couple of goals by Rooney yesterday it has definetely made by
weekend. Go on u reds!

Yesterday I bought the FT, The Times and The Sun (for sports pages) and today
The Sunday Times I did not find any articles regarding OXB. I have not managed
to find any recent news when I've flicked through the Bloomberg Business TV
Channel neither.

I'm sure this week will see the share price regain its upwards movement
towards 30p or drop close to 21p.

After this post I'm not going anywhere near a computer for a week (will remind
me too much of work tee hee hee hee!while I'm off)however, I will find time to
follow events through watching Bloomberg.

Will the share price continue its upwards momentum? Will the price continue
its fall in the previous session? Tommorrow's session and the remainder of the
week will be interesting.

Look foward to reading all the comments on the board in a week's time.

Good Luck All!

This is very good news...


Oxford Biomedica signs Lentivector technology licensing agreement
AFX


LONDON (AFX) - Oxford BioMedica PLC said it has signed a further licence agreement for its LentiVector technology with a large unnamed biopharmaceutical company.

Under terms of the agreement, Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee, however further financial details were not disclosed.

The agreement permits the use of the company's proprietary LentiVector gene delivery system -- a powerful technology for the delivery of genes to a wide range of cell and tissue types -- for research activities.

'The versatility and safety of lentiviral vectors make them the system of choice for gene target validation in the drug discovery process as well as for the direct therapeutic applications in neurotherapy that Oxford BioMedica is pursuing,' Senior Vice President Commercial Development, Peter Nolan commented.

'We are pleased that an increasing number of companies are using the LentiVector technology and we expect to establish a number of new partnerships around the technology in the near future.'

etain.lavelle@afxnews.com

This is a strange company or at least the share dealings seem odd to me. I has a series of good news, but every time one would expect the price to go up it heads south.

I have read in a journal at the weekend that the opinion was that it looked good but suggested locking into profits if any.

I am well into profit and intend holding for the while but would like to know what am I missing.

Just checking in for a quick afternoon peek at the prices etc. Totally agree with you Fred - I suppose an rns which simply shows "more of the same" is initially viewed as neutral by prospective shareholders, whereas a totally new agreement is positive because it demonstrates that OXB technology has more wide-ranging applications? Other than that, I cannot understand the small reduction in the price. Perhaps it will shoot up tomorrow?

And your point Queen?

Looking at the 1 year chart - it is possible that we could soon see a rise to the mid-30s - if we are currently in the 2nd wave. Any TA experts out there to advise?

Thought better of it pachandl. Dull day again.

Shrewd Snapshot: Sputnik still orbiting Oxford
Published: 07:00 Thursday 03 February 2005 < PREV | 1 | 2 | 3 | 4 | NEXT >

Private investor Boris Jordan has bought yet more of Oxford Biomedica amid a string of shrewd deals at companies as diverse as PFI Infrastructure, Blavod Extreme Spirits and NewMedia Spark.

* American-born Russian banker Jordan has been steadily building a stake in 90 million Oxford Biomedica for the past few weeks through his Sputnik Group which is acting in concert with Garboldi Investment and Sulidad Invest & Trade.

His latest purchase of 200,000 shares at 23.62p each takes the Sputnik concert party's total stake in Oxford (OXB) to 12.775 million or 3.45%. His first purchase came at 17.5p in mid-January but since then it has surged as high as 27.5p after the company confirmed it was in merger talks.

It closed last night at 24.25p.

Sputnik is not the only notable investor to have bought shares in Oxford in recent days with Credit Agricole and UBS both building up significant stakes in recent days on behalf of clients through contracts for difference. Credit Agricole holds 7.34% and UBS 3.2%.

All quiet on the Western Front - nothing reported in the weekend press. OXB and ? are clearly talking in a leak-proof environment.

Don't worry, Pachandl as OXB will merge with a highflyer soon. It is cheap now at 23p.

Not yet Hlye:

Oxford Biomedica PLC
07 February 2005



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF
AMERICA, CANADA, AUSTRALIA OR JAPAN


Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')


Termination of discussions


On 19 January 2005 the Board of Oxford BioMedica announced that it had received
an approach from a third party regarding a potential merger, which may or may
not lead to an offer for the Company.


The Board of Oxford BioMedica announces that the discussions that followed this
unsolicited approach have terminated.


7 February 2005


Enquiries:


Oxford BioMedica plc Tel: +44 (0) 1865 783000
Professor Alan Kingsman, Chief Executive Officer

Rothschild Tel: +44 (0) 20 7280 5000
Dr. Lynn Drummond


N M Rothschild & Sons Limited ('Rothschild'), which is authorised and regulated
by the Financial Services Authority in the United Kingdom, acts for Oxford
BioMedica plc and no one else in relation to the contents of this announcement
and will not be responsible to anyone other than Oxford BioMedica plc for
providing the protections afforded to clients of Rothschild nor for providing
advice in relation to the contents of this announcement.


This information is provided by RNS
The company news service from the London Stock Exchange

see this one free fall for a week or so. Some very good news is now required to get this one back on track.

It had better be good...this was NOT the way to treat their shareholders....very autocratic.So,do we all pile back in at 14.50???Can someone inform me as to how much of their research is based on animal experiments.Thanks.